The multi-faceted roles of prostaglandin E2 in cancer-infiltrating mononuclear phagocyte biology

Immunobiology

Volumn 217, Issue 12, 2012, Pages 1225-1232

  Sha, Weixiao ^a   Brüne, Bernhard ^a   Weigert, Andreas ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Cancer; Dendritic cell; Inflammation; Lipids; Macrophage; MDSC

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; SORAFENIB;

ARTICLE; BREAST CANCER; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CELL INFILTRATION; COLORECTAL CANCER; DENDRITIC CELL; HUMAN; IMMUNOREGULATION; INFLAMMATION; INTESTINE TUMOR; KIDNEY CANCER; LIVER CANCER; MACROPHAGE; MONOCYTE; MONONUCLEAR PHAGOCYTE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DINOPROSTONE; HUMANS; INFLAMMATION; MONONUCLEAR PHAGOCYTE SYSTEM; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84869092549     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.05.001     Document Type: Article

References (112)

1. Bage T., Lindberg J., Lundeberg J., Modeer T., Yucel-Lindberg T. Signal pathways JNK and NF-kappaB, identified by global gene expression profiling, are involved in regulation of TNFalpha-induced mPGES-1 and COX-2 expression in gingival fibroblasts. BMC Genomics 2010, 11:241.
2. Balsinde J., Winstead M.V., Dennis E.A. Phospholipase A(2) regulation of arachidonic acid mobilization. FEBS Lett. 2002, 531:2-6.
3. Ban J.O., Kwak D.H., Oh J.H., Park E.J., Cho M.C., Song H.S., Song M.J., Han S.B., Moon D.C., Kang K.W., Hong J.T. Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chem. Biol. Interact. 2010, 188:75-85.
4. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., Huhn R.D., Song W., Li D., Sharp L.L., Torigian D.A., O'Dwyer P.J., Vonderheide R.H. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
5. Bekeredjian-Ding I., Schafer M., Hartmann E., Pries R., Parcina M., Schneider P., Giese T., Endres S., Wollenberg B., Hartmann G. Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha. Immunology 2009, 128:439-450.
6. Bell D., Chomarat P., Broyles D., Netto G., Harb G.M., Lebecque S., Valladeau J., Davoust J., Palucka K.A., Banchereau J. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 1999, 190:1417-1426.
7. Bezugla Y., Kolada A., Kamionka S., Bernard B., Scheibe R., Dieter P. COX-1 and COX-2 contribute differentially to the LPS-induced release of PGE2 and TxA2 in liver macrophages. Prostaglandins Other Lipid Mediat. 2006, 79:93-100.
8. Bianchini F., Massi D., Marconi C., Franchi A., Baroni G., Santucci M., Mannini A., Mugnai G., Calorini L. Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression. Prostaglandins Other Lipid Mediat. 2007, 83:320-328.
9. Boniface K., Bak-Jensen K.S., Li Y., Blumenschein W.M., McGeachy M.J., McClanahan T.K., McKenzie B.S., Kastelein R.A., Cua D.J., de Waal Malefyt R. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J. Exp. Med. 2009, 206:535-548.
10. Brecht K., Weigert A., Hu J., Popp R., Fisslthaler B., Korff T., Fleming I., Geisslinger G., Brune B. Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2. FASEB J. 2011, 25:2408-2417.
11. Brenneis C., Coste O., Altenrath K., Angioni C., Schmidt H., Schuh C.D., Zhang D.D., Henke M., Weigert A., Brune B., Rubin B., Nusing R., Scholich K., Geisslinger G. Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation. J. Biol. Chem. 2011, 286:2331-2342.
12. Bystrom J., Evans I., Newson J., Stables M., Toor I., van Rooijen N., Crawford M., Colville-Nash P., Farrow S., Gilroy D.W. Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood 2008, 112:4117-4127.
13. Chan A.T., Cook N.R. Are we ready to recommend aspirin for cancer prevention?. Lancet 2012.
14. Chow A., Brown B.D., Merad M. Studying the mononuclear phagocyte system in the molecular age. Nat. Rev. Immunol. 2011, 11:788-798.
15. Donkor M.K., Lahue E., Hoke T.A., Shafer L.R., Coskun U., Solheim J.C., Gulen D., Bishay J., Talmadge J.E. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int. Immunopharmacol. 2009, 9:937-948.
16. Drobits B., Holcmann M., Amberg N., Swiecki M., Grundtner R., Hammer M., Colonna M., Sibilia M. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J. Clin. Invest. 2012, 122:575-585.
17. Duff M., Stapleton P.P., Mestre J.R., Maddali S., Smyth G.P., Yan Z., Freeman T.A., Daly J.M. Cyclooxygenase-2 inhibition improves macrophage function in melanoma and increases the antineoplastic activity of interferon gamma. Ann. Surg. Oncol. 2003, 10:305-313.
18. Edwards J.P., Emens L.A. The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE in murine macrophages. Int. Immunopharmacol. 2010, 10:1220-1228.
19. Eisengart C.A., Mestre J.R., Naama H.A., Mackrell P.J., Rivadeneira D.E., Murphy E.M., Stapleton P.P., Daly J.M. Prostaglandins regulate melanoma-induced cytokine production in macrophages. Cell Immunol. 2000, 204:143-149.
20. Elander N., Ungerback J., Olsson H., Uematsu S., Akira S., Soderkvist P. Genetic deletion of mPGES-1 accelerates intestinal tumorigenesis in APC(Min/+) mice. Biochem. Biophys. Res. Commun. 2008, 372:249-253.
21. Engelhardt J.J., Boldajipour B., Beemiller P., Pandurangi P., Sorensen C., Werb Z., Egeblad M., Krummel M.F. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 2012, 21:402-417.
22. Eruslanov E., Daurkin I., Ortiz J., Vieweg J., Kusmartsev S. Pivotal advance: tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE catabolism in myeloid cells. J. Leukoc. Biol. 2010, 88:839-848.
23. Eruslanov E., Kaliberov S., Daurkin I., Kaliberova L., Buchsbaum D., Vieweg J., Kusmartsev S. Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. J. Immunol. 2009, 182:7548-7557.
24. Escorcio-Correia M., Hagemann T. Measurement of tumor cytolysis by macrophages. Curr. Protoc. Immunol. 2011, 18:1-11. Chapter 14, Unit 14.
25. Fabricius D., Neubauer M., Mandel B., Schutz C., Viardot A., Vollmer A., Jahrsdorfer B., Debatin K.M. Prostaglandin E2 inhibits IFN-alpha secretion and Th1 costimulation by human plasmacytoid dendritic cells via E-prostanoid 2 and E-prostanoid 4 receptor engagement. J. Immunol. 2010, 184:677-684.
26. Fujita M., Kohanbash G., Fellows-Mayle W., Hamilton R.L., Komohara Y., Decker S.A., Ohlfest J.R., Okada H. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 2011, 71:2664-2674.
27. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
28. Gerlini G., Urso C., Mariotti G., Di Gennaro P., Palli D., Brandani P., Salvadori A., Pimpinelli N., Reali U.M., Borgognoni L. Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin. Immunol. 2007, 125:184-193.
29. Gilliet M., Cao W., Liu Y.J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 2008, 8:594-606.
30. Greenhough A., Smartt H.J., Moore A.E., Roberts H.R., Williams A.C., Paraskeva C., Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386.
31. Gregory C.D., Pound J.D. Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues. J. Pathol. 2010, 223:177-194.
32. Habenicht A.J., Goerig M., Grulich J., Rothe D., Gronwald R., Loth U., Schettler G., Kommerell B., Ross R. Human platelet-derived growth factor stimulates prostaglandin synthesis by activation and by rapid de novo synthesis of cyclooxygenase. J. Clin. Invest. 1985, 75:1381-1387.
33. Hanaka H., Pawelzik S.C., Johnsen J.I., Rakonjac M., Terawaki K., Rasmuson A., Sveinbjornsson B., Schumacher M.C., Hamberg M., Samuelsson B., Jakobsson P.J., Kogner P., Radmark O. Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:18757-18762.
34. Harris R.E. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 2009, 17:55-67.
35. Herber D.L., Cao W., Nefedova Y., Novitskiy S.V., Nagaraj S., Tyurin V.A., Corzo A., Cho H.I., Celis E., Lennox B., Knight S.C., Padhya T., McCaffrey T.V., McCaffrey J.C., Antonia S., Fishman M., Ferris R.L., Kagan V.E., Gabrilovich D.I. Lipid accumulation and dendritic cell dysfunction in cancer. Nat. Med. 2010, 16:880-886.
36. Herfs M., Herman L., Hubert P., Minner F., Arafa M., Roncarati P., Henrotin Y., Boniver J., Delvenne P. High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells. Cancer Immunol. Immunother. 2009, 58:603-614.
37. Heusinkveld M., de Vos van Steenwijk P.J., Goedemans R., Ramwadhdoebe T.H., Gorter A., Welters M.J., van Hall T., van der Burg S.H. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J. Immunol. 2011, 187:1157-1165.
38. Honda A., Sugimoto Y., Namba T., Watabe A., Irie A., Negishi M., Narumiya S., Ichikawa A. Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. J. Biol. Chem. 1993, 268:7759-7762.
39. Hou Z., Falcone D.J., Subbaramaiah K., Dannenberg A.J. Macrophages induce COX-2 expression in breast cancer cells: role of IL-1beta autoamplification. Carcinogenesis 2011, 32:695-702.
40. Huang Q., Li F., Liu X., Li W., Shi W., Liu F.F., O'Sullivan B., He Z., Peng Y., Tan A.C., Zhou L., Shen J., Han G., Wang X.J., Thorburn J., Thorburn A., Jimeno A., Raben D., Bedford J.S., Li C.Y. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat. Med. 2011, 17:860-866.
41. Ikegami R., Sugimoto Y., Segi E., Katsuyama M., Karahashi H., Amano F., Maruyama T., Yamane H., Tsuchiya S., Ichikawa A. The expression of prostaglandin E receptors EP2 and EP4 and their different regulation by lipopolysaccharide in C3H/HeN peritoneal macrophages. J. Immunol. 2001, 166:4689-4696.
42. Israel D.D., Regan J.W. EP(3) prostanoid receptor isoforms utilize distinct mechanisms to regulate ERK 1/2 activation. Biochim. Biophys. Acta 2009, 1791:238-245.
43. Jakobsson P.J., Thoren S., Morgenstern R., Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:7220-7225.
44. Jensen T.O., Schmidt H., Moller H.J., Donskov F., Hoyer M., Sjoegren P., Christensen I.J., Steiniche T. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 2011, Published online ahead of print.
45. Johann A.M., Weigert A., Eberhardt W., Kuhn A.M., Barra V., von Knethen A., Pfeilschifter J.M., Brune B. Apoptotic cell-derived sphingosine-1-phosphate promotes HuR-dependent cyclooxygenase-2 mRNA stabilization and protein expression. J. Immunol. 2008, 180:1239-1248.
46. Kalinski P. Regulation of immune responses by prostaglandin E2. J. Immunol. 2012, 188:21-28.
47. Kamata H., Hosono K., Suzuki T., Ogawa Y., Kubo H., Katoh H., Ito Y., Uematsu S., Akira S., Watanabe M., Majima M. mPGES-1-expressing bone marrow-derived cells enhance tumor growth and angiogenesis in mice. Biomed. Pharmacother. 2010, 64:409-416.
48. Kambayashi T., Alexander H.R., Fong M., Strassmann G. Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J. Immunol. 1995, 154:3383-3390.
49. Kamei D., Murakami M., Sasaki Y., Nakatani Y., Majima M., Ishikawa Y., Ishii T., Uematsu S., Akira S., Hara S., Kudo I. Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis. Biochem. J. 2010, 425:361-371.
50. Karnezis T., Shayan R., Caesar C., Roufail S., Harris N.C., Ardipradja K., Zhang Y.F., Williams S.P., Farnsworth R.H., Chai M.G., Rupasinghe T.W., Tull D.L., Baldwin M.E., Sloan E.K., Fox S.B., Achen M.G., Stacker S.A. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell 2012, 21:181-195.
51. Kerkar S.P., Goldszmid R.S., Muranski P., Chinnasamy D., Yu Z., Reger R.N., Leonardi A.J., Morgan R.A., Wang E., Marincola F.M., Trinchieri G., Rosenberg S.A., Restifo N.P. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 2011, 121:4746-4757.
52. Kreiter S., Diken M., Selmi A., Diekmann J., Attig S., Husemann Y., Koslowski M., Huber C., Tureci O., Sahin U. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Res. 2011, 71:6132-6142.
53. Kuraishy A., Karin M., Grivennikov S.I. Tumor promotion via injury- and death-induced inflammation. Immunity 2011, 35:467-477.
54. Labidi-Galy S.I., Sisirak V., Meeus P., Gobert M., Treilleux I., Bajard A., Combes J.D., Faget J., Mithieux F., Cassignol A., Tredan O., Durand I., Menetrier-Caux C., Caux C., Blay J.Y., Ray-Coquard I., Bendriss-Vermare N. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res. 2011, 71:5423-5434.
55. Laoui D., Van Overmeire E., Movahedi K., Van den Bossche J., Schouppe E., Mommer C., Nikolaou A., Morias Y., De Baetselier P., Van Ginderachter J.A. Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. Immunobiology 2011, 216:1192-1202.
56. Lechner M.G., Liebertz D.J., Epstein A.L. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J. Immunol. 2010, 185:2273-2284.
57. Ley S., Weigert A., Brune B. Neuromediators in inflammation - a macrophage/nerve connection. Immunobiology 2010, 215:674-684.
58. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
59. Matta B.M., Castellaneta A., Thomson A.W. Tolerogenic plasmacytoid DC. Eur. J. Immunol. 2010, 40:2667-2676.
60. McDonnell A.M., Robinson B.W., Currie A.J. Tumor antigen cross-presentation and the dendritic cell: where it all begins?. Clin. Dev. Immunol. 2010, 2010:539519.
61. Medeiros A.I., Serezani C.H., Lee S.P., Peters-Golden M. Efferocytosis impairs pulmonary macrophage and lung antibacterial function via PGE2/EP2 signaling. J. Exp. Med. 2009, 206:61-68.
62. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8:958-969.
63. Murakami M., Kudo I. Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog. Lipid Res. 2004, 43:3-35.
64. Murakami M., Naraba H., Tanioka T., Semmyo N., Nakatani Y., Kojima F., Ikeda T., Fueki M., Ueno A., Oh S., Kudo I. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J. Biol. Chem. 2000, 275:32783-32792.
65. Muthuswamy R., Mueller-Berghaus J., Haberkorn U., Reinhart T.A., Schadendorf D., Kalinski P. PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood 2010, 116:1454-1459.
66. Nakanishi M., Montrose D.C., Clark P., Nambiar P.R., Belinsky G.S., Claffey K.P., Xu D., Rosenberg D.W. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res. 2008, 68:3251-3259.
67. Nakanishi Y., Nakatsuji M., Seno H., Ishizu S., Akitake-Kawano R., Kanda K., Ueo T., Komekado H., Kawada M., Minami M., Chiba T. COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps. Carcinogenesis 2011, 32:1333-1339.
68. Nakano Y., Kuroda E., Kito T., Yokota A., Yamashita U. Induction of macrophagic prostaglandin E2 synthesis by glioma cells. J. Neurosurg. 2006, 104:574-582.
69. Nemeth K., Leelahavanichkul A., Yuen P.S., Mayer B., Parmelee A., Doi K., Robey P.G., Leelahavanichkul K., Koller B.H., Brown J.M., Hu X., Jelinek I., Star R.A., Mezey E. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 2009, 15:42-49.
70. Nierkens S., den Brok M.H., Garcia Z., Togher S., Wagenaars J., Wassink M., Boon L., Ruers T.J., Figdor C.G., Schoenberger S.P., Adema G.J., Janssen E.M. Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res. 2011, 71:6428-6437.
71. Obermajer N., Muthuswamy R., Lesnock J., Edwards R.P., Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011, 118:5498-5505.
72. Obermajer N., Muthuswamy R., Odunsi K., Edwards R.P., Kalinski P. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 2011, 71:7463-7470.
73. Ojalvo L.S., Whittaker C.A., Condeelis J.S., Pollard J.W. Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J. Immunol. 2010, 184:702-712.
74. Oshima H., Oshima M., Inaba K., Taketo M.M. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J. 2004, 23:1669-1678.
75. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 2009, 182:4499-4506.
76. Palucka K., Banchereau J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 2012, 12:265-277.
77. Peters-Golden M. Putting on the brakes: cyclic AMP as a multipronged controller of macrophage function. Sci. Signal. 2009, 2:pe37.
78. Pollard J.W. Trophic macrophages in development and disease. Nat. Rev. Immunol. 2009, 9:259-270.
79. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
80. Ratcliffe M.J., Walding A., Shelton P.A., Flaherty A., Dougall I.G. Activation of E-prostanoid4 and E-prostanoid2 receptors inhibits TNF-alpha release from human alveolar macrophages. Eur. Respir. J. 2007, 29:986-994.
81. Rodriguez P.C., Hernandez C.P., Quiceno D., Dubinett S.M., Zabaleta J., Ochoa J.B., Gilbert J., Ochoa A.C. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 2005, 202:931-939.
82. Sakata D., Yao C., Narumiya S. Emerging roles of prostanoids in T cell-mediated immunity. IUBMB Life 2010, 62:591-596.
83. Samuelsson B., Morgenstern R., Jakobsson P.J. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol. Rev. 2007, 59:207-224.
84. Sasaki Y., Kamei D., Ishikawa Y., Ishii T., Uematsu S., Akira S., Murakami M., Hara S. Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis. Oncogene 2011, Published online ahead of print.
85. Scarlett U.K., Rutkowski M.R., Rauwerdink A.M., Fields J., Escovar-Fadul X., Baird J., Cubillos-Ruiz J.R., Jacobs A.C., Gonzalez J.L., Weaver J., Fiering S., Conejo-Garcia J.R. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J. Exp. Med. 2012, 209:495-506.
86. Schafer M., Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat. Rev. Mol. Cell. Biol. 2008, 9:628-638.
87. Scher J.U., Pillinger M.H. 15d-PGJ2: the anti-inflammatory prostaglandin?. Clin. Immunol. 2005, 114:100-109.
88. Serhan C.N., Savill J. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 2005, 6:1191-1197.
89. Sharma S., Stolina M., Yang S.C., Baratelli F., Lin J.F., Atianzar K., Luo J., Zhu L., Lin Y., Huang M., Dohadwala M., Batra R.K., Dubinett S.M. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin. Cancer Res. 2003, 9:961-968.
90. Sinha P., Clements V.K., Fulton A.M., Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007, 67:4507-4513.
91. Sombroek C.C., Stam A.G., Masterson A.J., Lougheed S.M., Schakel M.J., Meijer C.J., Pinedo H.M., van den Eertwegh A.J., Scheper R.J., de Gruijl T.D. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 2002, 168:4333-4343.
92. Swiecki M., Gilfillan S., Vermi W., Wang Y., Colonna M. Plasmacytoid dendritic cell ablation impacts early interferon responses and antiviral NK and CD8(+) T cell accrual. Immunity 2010, 33:955-966.
93. Tai H.H., Ensor C.M., Tong M., Zhou H., Yan F. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat. 2002, 68-69:483-493.
94. Talmadge J.E., Hood K.C., Zobel L.C., Shafer L.R., Coles M., Toth B. Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. Int. Immunopharmacol. 2007, 7:140-151.
95. Tanikawa N., Ohmiya Y., Ohkubo H., Hashimoto K., Kangawa K., Kojima M., Ito S., Watanabe K. Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. Biochem. Biophys. Res. Commun. 2002, 291:884-889.
96. Tanioka T., Nakatani Y., Semmyo N., Murakami M., Kudo I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J. Biol. Chem. 2000, 275:32775-32782.
97. Tel J., van der Leun A.M., Figdor C.G., Torensma R., de Vries I.J. Harnessing human plasmacytoid dendritic cells as professional APCs. Cancer Immunol. Immunother. 2012, Published online ahead of print.
98. Ting C.C., Hargrove M.E. Tumor cell-triggered macrophage-mediated suppression of the T-cell cytotoxic response to tumor-associated antigens. II. Mechanisms for induction of suppression. J. Natl. Cancer Inst. 1982, 69:873-878.
99. Tjiu J.W., Chen J.S., Shun C.T., Lin S.J., Liao Y.H., Chu C.Y., Tsai T.F., Chiu H.C., Dai Y.S., Inoue H., Yang P.C., Kuo M.L., Jee S.H. Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J. Invest. Dermatol. 2009, 129:1016-1025.
100. Treffkorn L., Scheibe R., Maruyama T., Dieter P. PGE2 exerts its effect on the LPS-induced release of TNF-alpha, ET-1, IL-1alpha, IL-6 and IL-10 via the EP2 and EP4 receptor in rat liver macrophages. Prostaglandins Other Lipid Mediat. 2004, 74:113-123.
101. Tsai C.S., Chen F.H., Wang C.C., Huang H.L., Jung S.M., Wu C.J., Lee C.C., McBride W.H., Chiang C.S., Hong J.H. Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. Int. J. Radiat. Oncol. Biol. Phys. 2007, 68:499-507.
102. von Bergwelt-Baildon M.S., Popov A., Saric T., Chemnitz J., Classen S., Stoffel M.S., Fiore F., Roth U., Beyer M., Debey S., Wickenhauser C., Hanisch F.G., Schultze J.L. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 2006, 108:228-237.
103. Wang D., Dubois R.N. Eicosanoids and cancer. Nat. Rev. Cancer 2010, 10:181-193.
104. Wang D., Wang H., Shi Q., Katkuri S., Walhi W., Desvergne B., Das S.K., Dey S.K., DuBois R.N. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 2004, 6:285-295.
105. Watabe A., Sugimoto Y., Honda A., Irie A., Namba T., Negishi M., Ito S., Narumiya S., Ichikawa A. Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor. J. Biol. Chem. 1993, 268:20175-20178.
106. Weigert A., Cremer S., Schmidt M.V., von Knethen A., Angioni C., Geisslinger G., Brune B. Cleavage of sphingosine kinase 2 by caspase-1 provokes its release from apoptotic cells. Blood 2010, 115:3531-3540.
107. Weigert A., Schiffmann S., Sekar D., Ley S., Menrad H., Werno C., Grosch S., Geisslinger G., Brune B. Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti-inflammatory phenotype. Int. J. Cancer 2009, 125:2114-2121.
108. Weigert A., Weichand B., Brune B. S1P regulation of macrophage functions in the context of cancer. Anticancer Agents Med. Chem. 2011, 11:818-829.
109. Xia D., Wang D., Kim S.H., Katoh H., DuBois R.N. Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat. Med. 2012, 18:224-226.
110. Yang L., Yamagata N., Yadav R., Brandon S., Courtney R.L., Morrow J.D., Shyr Y., Boothby M., Joyce S., Carbone D.P., Breyer R.M. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J. Clin. Invest. 2003, 111:727-735.
111. Zhang Y., Liu Q., Zhang M., Yu Y., Liu X., Cao X. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J. Immunol. 2009, 182:3801-3808.
112. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005, 5:263-274.